Orthopedics > OCOSH Classification > Orthopaedic Procedures > Arthroplasty > Replacement Arthroplasty > The Use of Direct Factor Xa Inhibitors in the Prevention of Thromboembolism after Joint Replacement COA
Previous
The Use of Direct Factor Xa Inhibitors in the Prevention of Thromboembolism after Joint Replacement COA
Visit Resource Review It Rate It Bookmark It
Description: Rivaroxaban is the first oral direct Factor Xa inhibitor approved in Canada for the prevention of venous thromboembolism (VTE) following elective total hip replacement (THR) and total knee replacement (TKR) surgery. The purpose of this article is to review the available information on rivaroxaban. Bassam A. Masri, M.D., FRCSC COA Bulletin Issue 83 2008
Type: Reference Material
Author/Contact: Bassam A. Masri, M.D., FRCSC
Institution: COA
Primary Subject/Category:
- - OCOSH Classification: Complications: Venous Thromboembolism
- - OCOSH Classification: Orthopaedic Procedures: Arthroplasty: Replacement Arthroplasty
Submitted by: admin
Hits: 877
Added: Wed Jul 01 2009